-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced thatFeb 14, 2023
-
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- GracellFeb 13, 2023
-
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023 SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb.Feb 03, 2023
-
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a globalDec 10, 2022
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Nov. 23, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer,Nov 23, 2022
-
Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award [ <a href="pdf_files/newsarticle-asset-auto-20221116-8096.pdf" target="_blank">PDF
FasTCAR next-day manufacturing autologous CAR-T platform recognized with prestigious biotech innovation award SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 16, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicatedNov 16, 2022
-
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022 First clinical data from ongoing investigator-initiated trial (IIT) evaluating GC012F in newly-diagnosed multiple myeloma (NDMM) patientsNov 14, 2022
-
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical companyNov 03, 2022
-
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced thatOct 31, 2022
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, todayOct 24, 2022